obesity
‘Hugely disturbing’ rise in UK children with type 2 diabetes, report finds
August 14, 2017Medical Communications, Sales and Marketing childhood obesity, diabetes, healthcare, life sciences, obesity, pharma, pharmaceuticals
A report from the Royal College of Paediatrics and Child Health (RCPCH) has highlighted a “hugely disturbing” rise in cases …
FDA investigating intragastric obesity treatment linked to five deaths
August 14, 2017Medical Communications, Sales and Marketing life sciences, medicine, obesity, pharma, pharmaceutical
The FDA has launched an investigation after five deaths thought to be caused by an obesity treatment surgery in which …
Drug combinations can boost weight loss, research finds
July 19, 2017Research and Development biotech, drugs, healthcare, obesity, pharma, pharmaceuticals, weight loss
Researchers at the Perelman School of Medicine at the University of Pennsylvania have found that by combining specific hormone-based drugs …
Novo Nordisk forms academic partnership with Washington Uni
November 4, 2015Research and Development Novo Nordisk, diabetes, obesity
Novo Nordisk has launched a new research collaboration with researchers at the University of Washington, to develop new drugs for …
Innovative pipeline can transform obesity treatment, says GBI Research
October 8, 2015Research and Development obesity
While the current obesity treatment market has a high level of unmet need, the therapeutic landscape could be transformed by …
Pfizer in metabolic disease push
September 11, 2015Medical Communications, Research and Development AMRA, Pfizer, UK Biobank, med tech, metabolic disease, obesity
Pfizer has signed a research collaboration with a global medical health technology company, to investigate risk factors for metabolic conditions. …
Takeda hits major snags with Contrave and Alisertib
May 14, 2015Sales and Marketing Contrave, Takeda, alisertib, obesity, orexigen
Takeda is threatening to end its partnership with Orexigen to market the obesity drug Contrave, as allegations around its heart …
Novo Nordisk obesity drug is launched in the US
April 23, 2015Sales and Marketing Novo Nordisk, liraglutide, obesity, overweight, saxenda, world health organization
Novo Nordisk is rolling out its obesity drug Saxenda across the US for the treatment of obese adult patients. Saxanda …
Novo Nordisk obesity drug gets EU approval
March 24, 2015Sales and Marketing EMA, EU, FDA, Victoza, liraglutide, obesity, saxenda
Novo Nordisk’s obesity drug Saxenda has been approved by the European Commission for use across the EU. This approval follows …
Novo Nordisk obesity drug shows added benefits
March 9, 2015Sales and Marketing (liraglutide), Contrave, Novo Nordisk, Victoza, Xenical, liraglutide, obesity, saxenda, weight
New research by Novo Nordisk has suggested that its obesity drug Saxenda can help improve several other weight-related problems as …
Merck invests $450m in NGM Biopharma
February 23, 2015Sales and Marketing Merck, NGM Biopharma, NP201, diabetes, nonalcoholic steatohepatitis, obesity
Merck is to collaborate on drug development with biotech firm NGM Pharmaceuticals in a $450 million deal. The collaboration will …
Shire drug approved for binge eating disorder
February 2, 2015Sales and Marketing ADHD, FDA, Shire, Vyvanse, binge, eating, lisdexamfetamine dimesylate, obesity
Shire has become the first company to gain FDA approval for a treatment for binge eating disorder (BED) in adults …
FDA approves novel obesity device
January 16, 2015Medical Communications, Sales and Marketing EnteroMedics, FDA, Novo, VBLOC, diabetes, obesity, type 2
The US Food and Drug Administration has shown the green light to US firm EnteroMedics’ new obesity device VBLOC that …
FDA panel backs liraglutide for obesity
September 12, 2014Manufacturing and Production, Sales and Marketing Arena Pharmaceuticals, Belviq, Novo Nordisk, Qsymia, Victoza, Vivus, diabetes, obesity
An FDA panel has voted 14-1 to allow a form of Novo Nordisk’s type 2 diabetes treatment Victoza to help …
Fourth diet pill makes it to US market
September 11, 2014Manufacturing and Production, Sales and Marketing Contrave, FDA, Orexigen Therapeutics, diet, obesity
Orexigen Therapeutics has gained FDA approval for its new obesity treatment Contrave to help overweight patients reduce their food intake. …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
